Resources | NITAG RESOURCE CENTER

2024 ∙ NIAC

NIAC updated recommendations for COVID-19 primary schedule vaccination

2024 ∙ ACIP

Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the ACIP — United States, 2024

2024 ∙ ACIP

ACIP Evidence to Recommendations for Use of Protein Subunit RSV vaccines (GSK Arexvy or Pfizer Abrysvo) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease

2024 ∙ ACIP

ACIP Evidence to Recommendations for Use of Moderna RSV Vaccine (mResvia) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease

2024 ∙ ACIP

GRADE of Protein subunit RSV vaccines (GSK Arexvy and Pfizer Abrysvo) in older adults

2024 ∙ ACIP

GRADE of Moderna mRNA RSV Vaccine (mResvia) in older adults

2024 ∙ STIKO

Resolution on the STIKO recommendation for a standard vaccination against diseases caused by respiratory syncytial viruses (RSV) for persons ≥ 75 years of age and for the indication vaccination of persons aged 60 to 74 years with risk factors

2024 ∙ NACI

Statement on the prevention of respiratory syncytial virus disease in older adults

2024 ∙ ACIP

ACIP Evidence to Recommendations for Use of Protein Subunit RSV vaccines (GSK Arexvy or Pfizer Abrysvo) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease

2024 ∙ ACIP

ACIP Evidence to Recommendations for Use of Moderna RSV Vaccine (mResvia) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease